Flagship CF therapy, Trikafta, remains at the core of Vertex Pharma's pipeline push

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 10:06 PM ET. Details in the imprint.

With ever more treatment options competing for attention in rare diseases, Vertex Pharmaceuticals' cystic fibrosis combination therapy Trikafta remains the company's flagship product and primary growth engine, accounting for the bulk of its more than $10 billion in annual CF revenue and reaching tens of thousands of patients worldwide.

How Trikafta works and who it is for

Trikafta is a triple-combination regimen that combines the CFTR modulators elexacaftor, tezacaftor and ivacaftor, designed to correct the defective CFTR protein that underlies cystic fibrosis in patients with at least one F508del mutation in the CFTR gene. The therapy is approved in the US for eligible patients as young as 2 years old, in weight-adjusted dosing regimens that pair morning tablets of all three components with an evening dose of ivacaftor alone, reflecting the drug's pharmacokinetic profile and the need to maintain CFTR modulation over 24 hours. In pivotal studies, Trikafta produced clinically meaningful improvements in lung function measured as percent predicted FEV1, reductions in pulmonary exacerbations and gains in body mass index, outcomes that have translated into a significant shift in the prognosis for many people with cystic fibrosis who previously had limited disease-modifying options.

Outside the US, the combination is marketed as Kaftrio together with ivacaftor and has been rolled out across major European markets, Canada and other regions via a series of country-by-country reimbursement deals that often include outcomes-based or long-term agreements with public payers. Despite high list prices in wealthier markets, Vertex has emphasized that its CF franchise, led by Trikafta, now treats more than 75,000 patients across some 60 countries, and the company continues to expand eligibility by pursuing younger age groups and additional CFTR genotypes as supporting clinical data accumulate. At the same time, the success of Trikafta has prompted generic and access-focused initiatives in emerging markets: for example, Bangladesh-based Beximco Pharmaceuticals has developed TRIKO, a low-cost generic version of the elexacaftor-tezacaftor-ivacaftor combination, priced at about $12,750 per year for adults, which the company says represents roughly a 96 percent discount to the US list price of the originator therapy and is aimed at patients in countries where branded Trikafta is not widely reimbursed.

Within Vertex's broader portfolio, Trikafta continues to fund diversification into new areas such as gene-editing candidates for sickle cell disease and beta-thalassemia, as well as small-molecule programs in pain and kidney disease, but management consistently highlights that the CF franchise remains the foundation of the business and a key determinant of near-term cash flow. Shares of Vertex Pharmaceuticals (US92532F1003) traded on NASDAQ at around $480 in mid-June 2026, reflecting investor expectations that Trikafta's cash generation can support both continued CF investments and pipeline development beyond cystic fibrosis.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.